Anderson H, Thatcher N, Howell A, Logan K, Sage T, de Bruijn K M
Christie Hospital and Holt Radium Institute, Withington, Manchester, U.K.
Eur J Cancer. 1994;30A(5):610-5. doi: 10.1016/0959-8049(94)90530-4.
This randomised, open, parallel group study compared the antiemetic efficacy and tolerability of tropisetron with metoclopramide plus lorazepam in 102 patients receiving a first course of non-cisplatin-containing chemotherapy. Control of acute vomiting by tropisetron was significantly superior to that of the metoclopramide regimen, with total control (no vomiting) in 45% of 51 patients in the tropisetron group compared with 22% of 51 patients in the metoclopramide group (P = 0.013); total and partial control (< 5 vomits) occurred in 67 and 47% of patients, respectively (P = 0.044). The incidences of acute nausea and of delayed nausea and emesis were similar in the two treatment groups. Both tropisetron and metoclopramide were well tolerated; no adverse effects were attributed to tropisetron administration with the exception of headache. One patient in the metoclopramide group reported confusion and tremor thought to be related to the antiemetic therapy. Tropisetron is an effective and well-tolerated agent in the prevention of chemotherapy-induced vomiting. The control of acute nausea was similar in the two treatment groups, but tropisetron was superior to a metoclopramide-based regimen in the control of acute vomiting.
这项随机、开放、平行组研究比较了托烷司琼与甲氧氯普胺加劳拉西泮在102例接受不含顺铂的首次化疗疗程患者中的止吐疗效和耐受性。托烷司琼对急性呕吐的控制显著优于甲氧氯普胺方案，托烷司琼组51例患者中有45%完全控制（无呕吐），而甲氧氯普胺组51例患者中这一比例为22%（P = 0.013）；完全控制和部分控制（呕吐<5次）分别发生在67%和47%的患者中（P = 0.044）。两个治疗组急性恶心、延迟性恶心和呕吐的发生率相似。托烷司琼和甲氧氯普胺的耐受性均良好；除头痛外，未发现托烷司琼给药有不良反应。甲氧氯普胺组有1例患者报告出现意识模糊和震颤，认为与止吐治疗有关。托烷司琼是预防化疗引起呕吐的一种有效且耐受性良好的药物。两个治疗组对急性恶心的控制相似，但托烷司琼在控制急性呕吐方面优于基于甲氧氯普胺的方案。
